Anyway, let me attempt to unify, insofar as one can, the domain of opinion with the domain of reality.
Here's how I weigh the use of the following compounds for use in men (i.e., androgenicity & masculinizing effects do not reduce tolerability):
1. 1-Testosterone ("DHB")
2. Drostanolone ("Mast")
3. Metenolone ("Primo")
4. Stenbolone ("Sten")
2 > 3 > 4 > 1
Worked Example of a Rational Approach to Compound Selection
Efficacy (1st dimension):
Because, 1-testosterone, metenolone, & stenbolone are 1-enes, marked by reduced androgenic potency in man, these are attenuated androgens & all characterized by mild anabolic effects in man dissociated from markedly low androgenic effects; and are equivalent per-mg in anabolic potency.
1 ≈ 3 ≈ 4
Drostanolone was discontinued for its use in metastatic-resistant breast cancer because it was too androgenic (masculinizing in women), it is the more potent androgen among these drugs. It is, too, associated with more strength benefits, and it shows up quite often in positive doping control samples from strength & power athletes. Its particular benefit among the 4 is aggression & therefore strength via augmented neural drive (+1 for drostanolone). Albeit indirectly, strength increases permit more intense work & increased mechanical tension, in turn enhancing hypertrophy via training intensity.
(1 ≈ 3 ≈ 4) < 2
Tolerability (2nd dimension):
1-Testosterone is difficult to hold in solution, it crashes readily, and as a result, is anecdotally associated with severe PIP (-1), as well as, likely due to the use of solvents like guaiacol, to increases to C-reactive protein (-2; cardiovascular risks, &...); and increases to liver weight in a rodent model (-3 for 1-testosterone; plausible hepatotoxicity risks).
1 < (3 ≈ 4) < 2
Intramuscular injections are associated with pain & swelling at the injection site.
Metenolone, as enanthate (e.g., Rimobolan), & drostanolone as enanthate (i.e., "Mast E"), require only a moderately-long injection interval of every 7 - 10 days or their dose (fAUC) diminishes.
Stenbolone is available, as it was commercially as a pharmaceutical product, as stenbolone acetate. The acetate ester necessitates every 2 - 3 day injection frequencies or its dose (fAUC) diminishes rapidly (-1 for stenbolone).
1 < 4 < 3 < 2, proof of the opening claim.
I can continue this out further along the dimensions of tolerability & efficacy (e.g., per-mL potency), but all that I'll end up doing is continuing to prove this same statement.
Note: intangible & volatile factors like effects on mood, energy, libido, & wellbeing, and market factors (supply/demand/scarcity/price) are not weighed because they're simply labile & capricious, prone to tastes & preferences, psychology, trade, etc.